The new melatonin receptor ligands (UCM 976
, UCM 1032, UCM 1033 and UCM 1037) were synthesized as described in schemes 1-2. Briefly they were prepared by O-alkylation of N-acetyl-5-hydroxytryptamine with 1-bromo-4-phenylbutane in the presence of sodium hydride (UCM 976) and subsequent C2-indole halogenation with phenyltrimethylammonium tribromide (UCM 1032) or with iodine and silver triflate (UCM 1037) (Scheme 1). The 2-phenyl melatonin analogue (UCM 1033) was prepared from O-demethyl-2-phenylmelatonin (2-Ph-MLT: previously obtained by ether cleavage of 2-phenylmelatonin using boron tribromide) and 1-bromo-4-phenylbutane in the presence of sodium hydride (Scheme 2).
Experimental Section Chemistry
Melting points were determined on a Buchi B-540 capillary melting point apparatus and are uncorrected.
1 H NMR and 13 C NMR spectra were recorded on a Bruker AVANCE 200 or 400 instrument. Chemical shifts (δ scale) are reported in parts per million (ppm) relative to the central peak of the solvent. Coupling constants (J values) are given in hertz (Hz). ESI MS spectra were taken on a Waters Micromass ZQ instrument; only molecular ions [M+1] + are given. The purity of tested compounds, determined by high pressure liquid chromatography (HPLC), was greater than 95%. These analyses were performed on a Waters HPLC/UV/MS system (separation module Alliance HT2795, Photo Diode Array Detector 2996, mass detector Micromass ZQ; software: MassLynx 4.1). Column chromatography purifications were performed under "flash" conditions using Merck 230−400 mesh silica gel. Analytical thin-layer chromatography (TLC) was carried out on Merck silica gel 60 F 254 plates. N-Acetyl-5-hydroxytryptamine and 1-bromo-4-phenylbutane were purchased from commercial suppliers and used without further purification.
N-{2-[5-(4-Phenylbutoxy)-1H-indol-3-yl]ethyl} acetamide 1 (UCM 976)
NaH (80% in mineral oil, 80 mg, 2.66 mmol) and 1-bromo-4-phenylbutane (0.54 mL, 3.20 mmol) were added at 0°C under nitrogen to a solution of N-acetyl-5-hydroxytryptamine (540 mg, 2.48 mmol) in dry DMF (8 mL). The reaction mixture was stirred 24 h at room temperature, quenched by adding water and then extracted (3×) with EtOAc. The organic phases were combined, washed with brine, dried (Na 2 SO 4 ) and concentrated under reduced pressure to give a crude material which was purified by flash chromatography over silica gel (EtOAc as eluent). 
N-{2-[2-Iodo-5-(4-phenylbutoxy)-1H-indol-3-yl]ethyl} acetamide (UCM1037)
A solution of iodine (130 mg, 0.51 mmol) in dry THF (3 mL) was added dropwise to a solution of N-{2-[5-(4-phenylbutoxy)-1H-indol-3-yl]ethyl}acetamide (180 mg, 0.51 mmol) and AgOTf (159 mg, 0.62 mmol) in dry THF (3 mL). The reaction mixture was stirred 15 min at room temperature then quenched with saturated Na 2 S 2 O 3 and extracted (3×) with EtOAc. The organic phases were combined, washed with brine, dried (Na 2 SO 4 ) and concentrated under reduced pressure to give a crude material which was purified by flash chromatography over silica gel (EtOAc as eluent). Beige solid, mp 97-8°C (EtOAc-petroleum ether); 44% yield. CDCl 3 ) d 170.1, 153.7, 142.3, 134.1, 128.4, 128.3,  127.8, 125.8, 118.7, 113.1, 111.2, 100.6, 78.5, 68.6, 39 Hydroxy-2-phenyl-1H-indol-3-yl) ethyl] acetamide A solution of BBr 3 1M in CH 2 Cl 2 (0.9 mL, 0.9 mmol) in dry CH 2 Cl 2 (3 mL) was added dropwise at 0°C to a solution of 2-phenylmelatonin 2 (140 mg, 0.45 mmol) in dry CH 2 Cl 2 (3 mL) stirred under nitrogen atmosphere. The resulting mixture was stirred 20 h at room temperature, quenched by adding an aqueous saturated solution of NaHCO 3 until neutral pH and then extracted (3×) with CH 2 Cl 2 . The organic phases were combined, washed with brine, dried (Na 2 SO 4 ) and concentrated under reduced pressure to give a crude material which was purified by flash chromatography over silica gel (EtOAc as eluent). Grey solid, mp 181-2°C (Et 2 O); 82% yield. This compound was prepared according to the procedure described above for the synthesis of N-{2- starting from N-[2-(5-hydroxy-2-phenyl-1H-indol-3-yl 
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